⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
Form 8-K
sec.gov
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
globenewswire.com
AIM
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
globenewswire.com
AIM
International Sandberg Development to Build New U.S. Headquarters in Prince William County
businesswire.com
AIM